|
Clinical Trials and Observations
Citations 271-280 of 2742 total displayed.
|
Past content
(since May 1998):
|
Classification of lymphoid neoplasms: the microscope as a tool for disease discovery
- Elaine S. Jaffe, Nancy Lee Harris, Harald Stein, and Peter G. Isaacson
Blood 2008; 112: 4384-4399.
[Abstract]
[Full text]
[PDF]
Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation
- Corey Cutler, Kristen Stevenson, Haesook T. Kim, Paul Richardson, Vincent T. Ho, Erica Linden, Carolyn Revta, Ruth Ebert, Diane Warren, Sung Choi, John Koreth, Philippe Armand, Edwin Alyea, Shelly Carter, Mary Horowitz, Joseph H. Antin, and Robert Soiffer
Blood 2008; 112: 4425-4431.
[Abstract]
[Full text]
[PDF]
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial
- Clive Kearon, Jim A. Julian, Michael J. Kovacs, David R. Anderson, Philip Wells, Betsy MacKinnon, Jeffrey I. Weitz, Mark A. Crowther, Sean Dolan, Alexander G. Turpie, William Geerts, Susan Solymoss, Paul van Nguyen, Christine Demers, Susan R. Kahn, Jeannine Kassis, Marc Rodger, Julie Hambleton, Michael Gent, and Jeffrey S. Ginsberg, for the ELATE Investigators
Blood 2008; 112: 4432-4436.
[Abstract]
[Full text]
[PDF]
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
- David Marin, Dragana Milojkovic, Eduardo Olavarria, Jamshid S. Khorashad, Hugues de Lavallade, Alistair G. Reid, Letizia Foroni, Katayoun Rezvani, Marco Bua, Francesco Dazzi, Jiri Pavlu, Matthias Klammer, Jaspal S. Kaeda, John M. Goldman, and Jane F. Apperley
Blood 2008; 112: 4437-4444.
[Abstract]
[Full text]
[PDF]
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
- Michael Wang, Meletios A. Dimopoulos, Christine Chen, M. Teresa Cibeira, Michel Attal, Andrew Spencer, S. Vincent Rajkumar, Zhinuan Yu, Marta Olesnyckyj, Jerome B. Zeldis, Robert D. Knight, and Donna M. Weber
Blood 2008; 112: 4445-4451.
[Abstract]
[Full text]
[PDF]
Thalidomide and rituximab in Waldenstrom macroglobulinemia
- Steven P. Treon, Jacob D. Soumerai, Andrew R. Branagan, Zachary R. Hunter, Christopher J. Patterson, Leukothea Ioakimidis, Frederick M. Briccetti, Mark Pasmantier, Harvey Zimbler, Robert B. Cooper, Maria Moore, John Hill, II, Alan Rauch, Lawrence Garbo, Luis Chu, Cynthia Chua, Stephen H. Nantel, David R. Lovett, Hans Boedeker, Henry Sonneborn, John Howard, Paul Musto, Bryan T. Ciccarelli, Evdoxia Hatjiharissi, and Kenneth C. Anderson
Blood 2008; 112: 4452-4457.
[Abstract]
[Full text]
[PDF]
Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy
- Timothy P. Hughes, Susan Branford, Deborah L. White, John Reynolds, Rachel Koelmeyer, John F. Seymour, Kerry Taylor, Chris Arthur, Anthony Schwarer, James Morton, Julian Cooney, Michael F. Leahy, Philip Rowlings, John Catalano, Mark Hertzberg, Robin Filshie, Anthony K. Mills, Keith Fay, Simon Durrant, Henry Januszewicz, David Joske, Craig Underhill, Scott Dunkley, Kevin Lynch, and Andrew Grigg, on behalf of the Australasian Leukaemia and Lymphoma Group
Blood 2008; 112: 3965-3973.
[Abstract]
[Full text]
[PDF]
Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation
- Kenneth P. Micklethwaite, Leighton Clancy, Upinder Sandher, Anna M. Hansen, Emily Blyth, Vicki Antonenas, Mary M. Sartor, Kenneth F. Bradstock, and David J. Gottlieb
Blood 2008; 112: 3974-3981.
[Abstract]
[Full text]
[PDF]
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
- Michael N. Dworzak, Angela Schumich, Dieter Printz, Ulrike Pötschger, Zvenyslava Husak, Andishe Attarbaschi, Giuseppe Basso, Giuseppe Gaipa, Richard Ratei, Georg Mann, and Helmut Gadner
Blood 2008; 112: 3982-3988.
[Abstract]
[Full text]
[PDF]
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma
- Carsten Kobe, Markus Dietlein, Jeremy Franklin, Jana Markova, Andreas Lohri, Holger Amthauer, Susanne Klutmann, Wolfram H. Knapp, Josee M. Zijlstra, Andreas Bockisch, Matthias Weckesser, Reinhard Lorenz, Mathias Schreckenberger, Roland Bares, Hans T. Eich, Rolf-Peter Mueller, Michael Fuchs, Peter Borchmann, Harald Schicha, Volker Diehl, and Andreas Engert
Blood 2008; 112: 3989-3994.
[Abstract]
[Full text]
[PDF]
|
|
